In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented key findings from the DELTA 3 trial at the prestigious 82nd American Academy of Dermatology (AAD) Congress in San Diego, California. This marks the first public disclosure of the results […]
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global biopharmaceutical company, shared promising 48-week post-hoc analyses from the BE HEARD I and BE HEARD II Phase 3 studies of BIMZELX in adults with moderate-to-severe hidradenitis suppurativa (HS). These studies highlight clinically meaningful improvements in skin pain […]
